Table 1.

Patient Demographics and Characteristics

Patient Demographics and Characteristics	Total of patients N = 36
Gender (male), n (%)	14 (39)
Age at diagnosis, median, (IQR), years	6.5 (4.4–10.9)
Age at start adalimumab, median (IQR), years	10.5 (6.0–12.0)
Age at adalimumab through level, median (IQR), years	11.3 (7.1–13.0)
Time from diagnosis to adalimumab initiation, median (IQR), months	11.5 (4–33.5)
Time from adalimumab initiation to TL, median (IQR), weeks	37.5 (21–268)
Disease duration at TL, median (IQR), months	25.2 (12–56)
Weight at TL, median (IQR), kg	35 (21–52)
Weight corrected dose at TL, median (IQR), mg/kg body weight	0.85 (0.7–1.1)
Anatomical location of uveitis n (%)
Anterior uveitis	24 (67)
Intermediate uveitis	6 (17)
Posterior uveitis	2 (6)
Panuveitis	4 (11)
Anterior chamber cell count — no. (%)*
0.5 +	9 (25)
1 +	14 (39)
2 +	12 (33)
3 +	1 (3)
Laterality, n (%)
Unilateral	11 (31)
Bilateral	25 (69)
Etiological diagnosis n (%)
Juvenile idiopathic arthritis	19 (53)
Sarcoidosis	2 (6)
Idiopathic	15 (42)
Treatment
Previous Immunomodulators n (%)
Oral corticosteroids	13 (36)
Methotrexate	31 (86)
Cyclosporin A	4 (11)
Mycophenolate mofetil	1 (3)
Tacrolimus	1 (3)
Etanercept	1 (3)
Concomitant Immunomodulators n (%)
Methotrexate	21 (58)
Tacrolimus	1 (3)
Uveitis complications n (%)
Ocular hypertension/glaucoma	3 (8)
Cataract	9 (25)
Band keratopathy	4 (11)
Cystoid Macular edema	11 (31)
Macular epiretinal membrane	3 (8)
Optic disc swelling	5 (14)
Posterior synechia	11 (31)
Development of ADA, n (%)	2 (6)

IQR Inter Quartile Range, TL Through level, ADA Antidrug antibodies. In patients with bilateral uveitis, *the eye with higher grade of uveitis was chosen